BACKGROUND - To describe the incidence, morbidity and mortality of men who developed infectious complications requiring hospital admission following TRUS prostate biopsy in Victoria, Australia. Further it aimed to report the financial cost of these admissions.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS - The Department of Health's Victorian Admitted Episodes Data Set was used to identify those patients who underwent TRUS biopsy in Victoria who were subsequently readmitted within 7 days to any Victorian hospital with infective complications from July 2007 to June 2012. All Victorian public and private hospitals were included. Patients were excluded if their biopsy was performed during a multi-day admission. Financial costing data was obtained where available from the Department Of Health and Human Services for readmissions with post-TRUS infection where available and adjusted to 2012 prices. Institutional ethics committee approval was granted for this study.
RESULTS - 34,865 TRUS biopsies were performed in the 5-year period. 1276 (3.66%) were readmitted to a Victorian hospital within 7 days. 604 (1.73%) of these were readmitted with a biopsy-related infection. No significant trend in sepsis rates was seen in five years. The median readmission LOS was 4 days. The total burden of readmission was 3,686 days over 5 years. One patient readmitted with a biopsy related infection died during that episode of care. 20,051 (57.51%) of biopsies resulted in a diagnosis of prostate cancer. Financial costing data was available for 218 (36%) of infectious readmissions with a mean cost per readmission were $7,362 AUD (£4137 or $6844 USD, 95% CI $6219-8505 AUD) or $1,256 AUD per day.
CONCLUSIONS - Infection following TRUS biopsy was associated with a readmission rate for infection of 1 in 57 biopsies, an excess of 3,686 bed days required over 5 years with a cost of $1,256 AUD per day. The rate of infection remained stable for the period examined. This article is protected by copyright. All rights reserved.
BJU Int. 2015 Jul 14. doi: 10.1111/bju.13209. [Epub ahead of print]
Roth H1, Millar JL1,2,3, Cheng AC1,3, Byrne A4,5, Evans S2,3, Grummet J1,2.
1 Alfred Health, Melbourne, Australia.
2 Department of Surgery, Monash University, Melbourne, Australia.
3 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
4 North Eastern Melbourne Integrated Cancer Service, Melbourne, Australia.
5 Cancer Strategy and Development, Department of Health, Victoria, Australia.